|
|
||||||||
Department of Pathophysiology, AKH, Medical School, University of Vienna, A-1090 Vienna, Austria
1Correspondence: Department of Pathophysiology, AKH, EBO-3Q, Währinger Gürtel 1820, A-1090 Vienna, Austria. E-mail: erika.jensen-jarolim{at}akh-wien.ac.at
| ABSTRACT |
|---|
|
|
|---|
Key Words: Bet v 1 IgE epitope mimotope phage biopanning blocking IgG
| INTRODUCTION |
|---|
|
|
|---|
The phage display technique is relatively new, used to define peptide
structures that mimic natural epitopes, including conformational B cell
epitopes (16
17
18
19
20)
. Phage peptide libraries consist of
filamentous phages, displaying random peptides of defined length on
their surface either fused to the phage minor coat protein pIII
(21
, 22)
or, at a higher copy number, to the major coat
protein pVIII (23)
. Such peptide ligands can be selected
by biopanning. We have recently selected phage ligands for the
monoclonal anti-Bet v 1 IgG1 antibody BIP1 (24)
. The
identified ligand, termed Bet mim 1, represented a structure mimicking
a Bet v 1 epitope, which was not recognized by patients IgE. The
identified Bet v 1 epitope did thus represent an IgG epitope
(24)
.
In the present study, we defined an IgE epitope of Bet v 1. This seems of particular interest since IgE mimotopes could be used to precisely induce mono-epitope specific IgG acting potentially as blocking antibodies. We purified IgE from a serum pool of birch pollen allergic patients, which was applied in biopanning experiments. The properties of selected phage-displayed peptides representing mimotopes were compared to the sequence and 3-dimensional structure of Bet v 1 to localize the corresponding IgE epitope. IgE mimotopes were further used in immunization experiments with BALB/c mice for the induction of a blocking type of IgG.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Patients sera
Sera were collected from 12 patients with positive case history,
RAST classes > 4 and skin prick tests to birch pollen. All
patients showed intense IgE binding to Bet v 1 in immunoblot analysis.
Affinity purification of patients antibodies
Five milligrams of recombinant Bet v 1 (rBet v 1) (Biomay, Linz,
Austria) were dissolved in coupling buffer (0.2 M
NaHCO3, 0.5 M NaCl, pH 8.8) and mixed with
1.5 g CNBr-activated Sepharose 4B (Pharmacia, Uppsala, Sweden). To
block any remaining active groups, the gel was incubated with 1 M
ethanolamine (pH 9.0), then washed and packed into a glass column.
The serum pool was composed of equal volumes of sera from 12 birch pollen-allergic patients. The serum pool was diluted 1:2 in 0.9% (w/v) NaCl and dialyzed against 0.9% (w/v) NaCl prior to application to the affinity column. For each separation run (two runs were performed), 10 ml of diluted serum was loaded and recirculated overnight at 4°C. After extensive washing with 0.9% (w/v) NaCl, bound antibodies were eluted with 3 M KSCN in 5 mM phosphate buffer (pH 6.5). Eluted fractions were immediately neutralized and dialyzed against 0.9% (w/v) NaCl. Quantity and quality of eluents were checked with dot and blot immunoassays.
Dot assay
Purified immunoglobulins were dotted in triplicate onto
nitrocellulose (Schleicher & Schuell, Dassel, Germany). Dot blots were
air dried and saturated with TBS/0.05% Tween 20/1% powdered milk
before incubation with 125I-labeled anti-human
IgE or IgG (MALT Allergie system, IBL GmbH, Hamburg, Germany). Blots
were washed, dried, and exposed to Kodak Biomax MS autoradiography
films at -70°C.
Serial dilutions (40 ng, 20 ng, 10 ng, 5 ng/dot) of human IgE from an
immortalized B-cell line (SU-11, 26
) and human myeloma IgG
were prepared and dotted to nitrocellulose for subsequent quantity
estimation by density measurements with a hand-held reflexion
densitometer (Vipdens, Brixen, Italy).
SDS-PAGE, IgE, and IgG immunoblotting
Protein extracts were separated by 15% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) under reducing
conditions and transferred to Protran nitrocellulose membranes
(Schleicher & Schuell). Immunoblots were performed as described before,
using TBS/0,05% Tween 20/1% powdered milk for blocking, washing, and
antibody dilutions. Blotted proteins were incubated with patients
sera (diluted 1:5) overnight. After washing, bound IgE/IgG was detected
using 125I-labeled rabbit anti-human IgE or IgG
(MALT Allergie system) (1:20).
Alternately, blot strips were incubated with BIP 1 (25)
or
0590B2 hybridoma supernatant (14)
. Bound IgG was detected
using rabbit anti-mouse IgG (Nordic Immunology, London, U.K.), followed
by 125I-labeled donkey anti-rabbit IgG (Amersham,
Little Chalfont, U.K.), both diluted 1:1000.
Biopanning with phage libraries
Biopannings were performed using phage display libraries
expressing random linear (pVIII 9aa, ref 19
) or circular
(pVIII 9aa.Cys, ref 20
) nonapeptides fused to pVIII of the
filamentous bacteriophage VSCM13. Libraries were kindly provided by
IRBM (Istituto di Ricerce Biologia Moleculare, Rome, Italy).
Four successive panning rounds with affinity-purified human antibodies
were performed according to the method of Parmely and Smith
(22)
. For each round, 1 µg IgE in 0.1 M
NaHCO3 (pH 8.5) was coated on ELISA plates (Nunc,
Roskilde, Denmark). After blocking with phosphate-buffered saline
(PBS)/3% (w/v) bovine serum albumin at 37°C for 1 h,
108 pfu of freshly prepared phages from each
library were pooled and incubated with coated antibodies. After
extensive washing, bound phages were eluted and amplified by infecting
freshly grown Escherichia coli XL 1-blue and superinfection
with helper phage VSCM13 (1012 pfu/ml). Amplified
phage particles were precipitated with PEG, resuspended in TBS/0.15%
(w/v) casein, and used for the next panning round. Phagemide DNA was
prepared from overnight cultures of single phage clones; DNA sequencing
was performed by the Sanger didesoxy method using a Thermo Sequenase
cycle sequencing kit (Amersham) with fluorescent-labeled primers and
analyzed by a LI-COR DNA Sequencer 4000L (LI-COR Inc., Lincoln, Nebr.).
3-Dimensional epitope search
The 3-dimensional coarse-grained epitope search was based
on the X-ray structure of Bet v 1 (available in PDB format at the EMBL
protein database, entry 1BV1). For determination/fixation, each amino
acid was localized using the coordinates of its Cß atom (for glycine,
the C
atom). Based on this Cß grid, neighboring amino acids were
found in a distance smaller than 6.1 Å (upper limit of Cß-Cß
distance). Fitting of only two amino acids consecutively induced a
broader attempt, which allowed gaps (non fitting amino acids within the
nonapeptide sequence). The model was further simplified by classifying
all amino acids according to the chemical character of their residues:
a group of polar amino acids (N, Q, H, M, S, T), a group of lipophilic
amino acids (A, C, G, I, L, F, P, W, Y, V), a group of acidic amino
acids (D, E), and basic amino acids (R, K). All hits were statistically
evaluated.
Intraperitoneal immunization of BALB/c mice
Female BALB/c mice, 35 wk of age, were used for
intraperitoneal (i.p.) immunization with phages (Biovendor
Biotechnology, Brno, Czech Republic). For i.p. administration, 2 x 107 pfu phages were diluted to a volume of 100
µl in PBS. Three groups of three mice each were immunized on days 0,
14, and 28. Group A received phages expressing Bet mim E (CQQFLSVRALC),
group B received phages displaying a control peptide (CFFAWRSLPNC)
derived from biopannings with a murine monoclonal antibody directed to
a different birch pollen protein, and group C received the same amount
of PBS only.
Blood samples from the tail vein were taken on day 0 (preimmune serum), day 21, and day 38.
Inhibition experiments
Approximately 1 µg/cm natural Bet v 1 (nBet v 1) purified from
birch pollen extract using ion exchange chromatography, followed by
reversed phase HPLC, was separated by preparative 15% SDS-PAGE and
blotted onto nitrocellulose. Immunoblotting was performed as described
above, with slight modifications: after blocking, strips were first
incubated with mouse immune sera or, for control purposes, with
preimmune sera (1:250). After washing, strips were incubated with sera
from allergic patients (1:5). After washing, bound IgE were detected
with 125I-labeled anti-human IgE (MALT Allergie
system) and visualized by autoradiography. The percentage reduction of
IgE binding in relation to the uninhibited control (set to 100%) was
determined by densitometric analysis.
| RESULTS |
|---|
|
|
|---|
|
These purified antibodies were used in biopanning experiments. We
screened a repertoire of
2 x 108
different peptides by combining the pVIII 9aa and the pVIII
9aa.Cys libraries (19
, 20
, 23)
. After the fourth round
of selections, we defined five different peptides of possible ligands
by random selection. The deduced amino acid sequences are listed in
Table 1
.
|
Localization of the major IgE epitope of Bet v 1
Although linear alignments of the mimotope derived amino acid
sequences with the known amino acid sequence of Bet v 1 using the GCG
package (Genetics Computer Groups, Inc., Madison, Wis.) failed, a
3-dimensional epitope search resulted in statistically significant
amino acid similarities. Our approach was first based on homology
between neighboring residues permitting gaps. In another step of
abstraction, the amino acids were classified in four different
categories depending on the chemical character of their residues. Based
on this simplification, alignment with the derived sequences was
achieved without admission of gaps. Both approaches showed several
possible conformable amino acid positions. Therefore, all hits were
statistically evaluated. Significant accumulations in two regions,
including amino acids 922 and 104113, were found (Fig. 2A
). These two regions were neighboring and located on the
surface of the molecule. They covered an area of totally 500
Å2 and very likely compose a discontinuous IgE
epitope. As exemplified in Fig. 2A
, the area found was
localized between alpha-helix
1 and beta strands ß1, ß6, and
ß7. The corresponding mimotope was designated Bet mim E.
|
For control purposes, the 3-dimensional coarse-grained epitope search
was also applied for the localization of Bet mim 1, an IgG epitope of a
monoclonal murine anti-Bet v 1 antibody (BIP1; 24
, 25
)
(Fig. 2B
). The program identified the IgG epitope at
positions 5867, located in substantial distance of Bet mim E.
Induction of antibodies inhibiting human IgE binding
Phages displaying the peptide CQQFLSVRALC, derived from the pVIII
9aa.Cys (20)
library, were over-represented in round 4 of
the biopannings. Therefore, we selected this dominant clone for
immunization experiments in BALB/c mice. For control, phages displaying
a peptide (CFFAWRSLPNC) derived from biopannings with a monoclonal
antibody (BIP 3), directed to a different birch pollen protein
(25)
, or PBS alone, were delivered to BALB/c mice i.p. The
specific IgG response in sera of mice was analyzed by immunoblot
(Fig. 3
). All BALB/c mice immunized with phages displaying the Bet v 1 IgE
epitope developed IgG, which reacted with the 17 kDa allergen Bet v 1
in vitro (Fig. 3A
). In contrast, sera of mice
immunized with phages displaying the control peptide CFFAWRSLPNC or PBS
did not show any Bet v 1 specific reactivity (data not shown). The
specificity of IgG induced by immunization with Bet mim E phages was
further tested by inhibition experiments. IgG binding of mice immunized
with phages displaying the peptide CQQFLSVRALC was effectively
inhibited by preincubation of mouse immune sera with recombinant (r) or
natural (n) Bet v 1, but not after preincubation with an unrelated
protein (rBet v 2, birch profilin) (Fig. 3B
). These
experiments indicated that the peptide CQQFLSVRALC selected by
polyclonal patients IgE directed to Bet v 1 mimicked a Bet v 1
epitope.
|
To test the hypothesis of blocking IgG antibodies, we
investigated whether IgG specific for an IgE epitope was able to affect
the binding of human IgE to allergens. Nitrocellulose-blotted purified
allergens were first preincubated with sera from mice immunized with
phages displaying Bet mim E, and for control purposes, with preimmune
sera or a monoclonal antibody previously shown to block IgE binding
(14)
. As demonstrated in Fig. 4
, IgE binding of a serum pool from birch pollen allergic patients to
purified nBet v 1 was strongly inhibited after preincubation of the
membrane with IgG to Bet mim E or with monoclonal antibody 0590B2 14;
Fig. 4
, lanes 3 and 4). In contrast, IgE binding was not affected by a
monoclonal IgG antibody (BIP 1) directed to a distinct Bet v 1 epitope
(Bet mim 1) that was not recognized by IgE (24)
(Fig. 4
,
lane 5).
|
| DISCUSSION |
|---|
|
|
|---|
To localize the major IgE epitope, we developed a computer-aided
algorithm based on the 3-dimensional structure and the chemical
character of the amino acids. With this new method, it was possible to
localize the IgE epitope on the surface of Bet v 1 using mimotopes and
the known antigen structure. To our knowledge, a conformational IgE
epitope on the 3-dimensional structure of Bet v 1 is shown here for the
first time. Our data demonstrate that regions separated on the linear
amino acid sequence compose one patch on the surface of the allergen
and form a discontinuous IgE epitope. The position hits one of three
surface-exposed conserved patches common to all Bet v 1 homologues,
which were predicted by X-ray crystallography (6)
. It is
remarkable that the work of Ferreira et al. (12)
has shown
that point mutations in six critical amino acid positions lead to a
loss of allergenicity and that three of these amino acids (aa 10, 112,
113) are located within the computer determined epitope. Thus, our data
based on a rational approach confirm these previous findings deduced
from immunological properties of in vitro mutagenized Bet v
1.
According to our calculation, Bet mim E is located at a substantial
distance from Bet mim 1, an IgG epitope of the monoclonal murine
anti-Bet v 1 antibody BIP 1 (24
, 25)
. From serological
experiments we concluded that Bet mim 1 does not represent the binding
site for IgE (24)
. Based on sequence alignments, we had
previously speculated on a putative binding site of the monoclonal
antibody to Bet v 1 (31)
. With the
3-dimensional, coarse-grained epitope search, this assumption was
confirmed in the present study, again matching one of the three
conserved patches of Bet v 1 homologues published by Gajhede et al.
(6)
.
Whereas the role of IgE in the pathogenesis of type I allergy is well
established, much less is known concerning the effects of
allergen-specific IgG. A phenomenon accompanying specific immunotherapy
is the induction of allergen-specific IgG antibodies (32)
.
The determined IgG levels were without correlation to the clinical
outcome of immunotherapy (33)
. Recent studies indicated
that, depending on the epitope-specificity, IgG may enhance or inhibit
IgE binding to Bet v 1 by affecting the 3-dimensional conformation of
this molecule (14
, 15)
. In accordance, we could previously
demonstrate that IgG antibodies directed to a Bet v 1 epitope distinct
from the IgE epitope enhanced allergic skin reactivity in a murine
model (28)
. Using allergen molecules as a whole for
immunotherapy, it is not possible to predict which epitopes will be
targeted by IgG resulting in modulation of biological response.
Therefore, it is an attractive concept to use artificial epitopes
for immunotherapy, preferably a type inducing a blocking IgG
response. Such IgG directed to an IgE epitope may block the
IgEallergen interaction without sensitizing effector cells such as
mast cells or basophils via Fc
RI.
Therefore, the IgE mimotopes of Bet v 1 generated by biopanning of phage display peptide libraries were applied in immunization experiments. Mice immunized with IgE mimotopes showed an IgG response specific for Bet v 1 that was capable of blocking human IgE binding in vitro. Based on these observations, we conclude that the precise induction of blocking antibodies through mimotope vaccination inhibit consecutive IgE binding.
In this study, we present a strategy to define discontinuous IgE
epitopes with the phage display technology. More important, the
selected mimotopes were capable of inducing B-cell responses to the
natural conformational IgE epitope. In our opinion, this induction of
blocking IgG through IgE mimotope vaccination represents a
completely new principle for interfering with IgE-allergen
interactions. Moreover, for more than 90% of birch pollen allergic
patients who recognize Bet v 1 via IgE and 60% who recognize it
exclusively (4)
, the interference of IgE/Bet v 1
interaction by mimotope immunotherapy could also represent a promising
therapeutical concept.
| ACKNOWLEDGMENTS |
|---|
Received for publication December 15, 1999.
Revision received May 1, 2000.
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
A. B. Riemer, H. Kurz, M. Klinger, O. Scheiner, C. C. Zielinski, and E. Jensen-Jarolim Vaccination With Cetuximab Mimotopes and Biological Properties of Induced Anti-Epidermal Growth Factor Receptor Antibodies J Natl Cancer Inst, November 16, 2005; 97(22): 1663 - 1670. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Scholl, N. Kalkura, Y. Shedziankova, A. Bergmann, P. Verdino, R. Knittelfelder, T. Kopp, B. Hantusch, C. Betzel, K. Dierks, et al. Dimerization of the Major Birch Pollen Allergen Bet v 1 Is Important for its In Vivo IgE-Cross-Linking Potential in Mice J. Immunol., November 15, 2005; 175(10): 6645 - 6650. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Lionakis, J. Lahdenranta, J. Sun, W. Liu, R. E. Lewis, N. D. Albert, R. Pasqualini, W. Arap, and D. P. Kontoyiannis Development of a Ligand-Directed Approach To Study the Pathogenesis of Invasive Aspergillosis Infect. Immun., November 1, 2005; 73(11): 7747 - 7758. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Bresson, M. Cerutti, G. Devauchelle, M. Pugniere, F. Roquet, C. Bes, C. Bossard, T. Chardes, and S. Peraldi-Roux Localization of the Discontinuous Immunodominant Region Recognized by Human Anti-thyroperoxidase Autoantibodies in Autoimmune Thyroid Diseases J. Biol. Chem., March 7, 2003; 278(11): 9560 - 9569. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |